AbCellera Biologics Inc. Common Shares ABCL
Analyst Ratings
- Consensus
- Buy — 7 Buy · 1 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $15.13 (+35.9% upside)
Key Stats
- Today's Range
- $10.76 – $11.88
- 50-Day Range
- $10.32 – $15.02
- 52-Week Range
- $2.75 – $15.02
- Volume
- 4.16 million shs
- Average Volume
- 4.57 million shs
- Market Cap
- $3.98 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.31%
- Days to Cover
- 1.00
About AbCellera Biologics Inc. Common Shares
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Related Stocks
Compare head-to-head: ABCL vs LLY·ABCL vs JNJ·ABCL vs ABBV·ABCL vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.